medical technology

With a 20-year CAGR of 14.1%, Thermo Fisher has repeatedly shown how temporary headwinds create long-term value for patient shareholders.

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also strategically positioned to capitalise on future...

ResMed (ASX:RMD) reported its June quarter and full year results after the U.S. market closed on Friday morning. The company met consensus expectations for both...

There are several very good reasons why now is an ideal time to favour active investing over passive investing

Don't sleep on this alternative treatment to CPAP in the massive and growing obstructive sleep apnea market

With the healthcare sector in a deep and prolonged downturn, valuations of public and private R&D stage companies are very attractive.

Pulsed Field Ablation is the most exciting technology to come to market in many years, and offers great potential returns for the winners

Uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts.

A new world calls for discipline around the fundamentals while being open to opportunities.

The knock is that it is overpriced, but people said the same thing about CSL.

Often regarded as investor enemy number #1, uncertainty and volatility are key drivers of the short-term thinking that is so dominant in the retail market currently. ...

If Lazard Asset Management's Ronald Temple is right about his outlook for 2022, you might want to rethink some of those bullish bets. Here, Livewire's Glenn Freeman...